Share-based Payment Arrangement, Expense of Enveric Biosciences, Inc. from 31 Dec 2016 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Enveric Biosciences, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2016 to 30 Sep 2025.
  • Enveric Biosciences, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $186,567, a 49% decline year-over-year.
  • Enveric Biosciences, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $965,224, a 34% decline year-over-year.
  • Enveric Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $1,475,947, a 26% decline from 2023.
  • Enveric Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1,994,085, a 17% decline from 2022.
  • Enveric Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2,416,266, a 80% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Enveric Biosciences, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $965,224 $186,567 -$182,633 -49% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 $1,147,857 $205,846 -$163,354 -44% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $1,311,211 $193,434 -$164,736 -46% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $1,475,947 $379,377 +$23,657 +6.6% 01 Oct 2024 31 Dec 2024 10-K 28 Mar 2025 2024 FY
Q3 2024 $1,452,290 $369,200 +$40,947 +12% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2025 Q3
Q2 2024 $1,411,343 $369,200 -$456,163 -55% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $1,867,506 $358,170 -$126,579 -26% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $1,994,085 $355,720 -$127,993 -26% 01 Oct 2023 31 Dec 2023 10-K 28 Mar 2025 2024 FY
Q3 2023 $2,122,078 $328,253 -$261,937 -44% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $2,384,015 $825,363 +$202,767 +33% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $2,181,248 $484,749 -$235,018 -33% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $2,416,266 $483,713 -$7,043,900 -94% 01 Oct 2022 31 Dec 2022 10-K 26 Mar 2024 2023 FY
Q3 2022 $9,460,166 $590,190 +$155,787 +36% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $9,304,379 $622,596 -$160,449 -20% 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023 2023 Q2
Q1 2022 $9,464,828 $719,767 -$2,839,686 -80% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $12,304,514 $7,527,613 01 Oct 2021 31 Dec 2021 10-K/A 09 Jun 2023 2022 FY
Q3 2021 $434,403 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $783,045 01 Apr 2021 30 Jun 2021 10-Q 12 Aug 2022 2022 Q2
Q1 2021 $3,559,453 +$3,539,643 +17868% 01 Jan 2021 31 Mar 2021 10-Q 13 May 2022 2022 Q1
Q1 2020 $19,810 -$280,190 -93% 01 Jan 2020 31 Mar 2020 10-Q 15 May 2020 2020 Q1
Q1 2019 $300,000 $0 0% 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020 2020 Q1
Q1 2018 $300,000 -$202,254 -40% 01 Jan 2018 31 Mar 2018 10-Q 14 May 2019 2019 Q1
Q1 2017 $502,254 01 Jan 2017 31 Mar 2017 10-Q/A 15 May 2017 2017 Q1

Enveric Biosciences, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $1,475,947 -$518,138 -26% 01 Jan 2024 31 Dec 2024 10-K 28 Mar 2025 2024 FY
2023 $1,994,085 -$422,181 -17% 01 Jan 2023 31 Dec 2023 10-K 28 Mar 2025 2024 FY
2022 $2,416,266 -$9,888,248 -80% 01 Jan 2022 31 Dec 2022 10-K 26 Mar 2024 2023 FY
2021 $12,304,514 01 Jan 2021 31 Dec 2021 10-K/A 09 Jun 2023 2022 FY
2019 $1,200,000 +$600,000 +100% 01 Jan 2019 31 Dec 2019 10-K/A 12 Aug 2020 2019 FY
2018 $600,000 -$6,500,000 -92% 01 Jan 2018 31 Dec 2018 10-K/A 12 Aug 2020 2019 FY
2017 $7,100,000 +$5,600,000 +373% 01 Jan 2017 31 Dec 2017 10-K 26 Mar 2019 2018 FY
2016 $1,500,000 01 Jan 2016 31 Dec 2016 10-K 02 Apr 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.